Actavalon, a JLABS San Diego company, is developing novel approaches to cancer therapy by restoring p53 tumor suppression activity lost by mutation in more than 50% of cancers. As an early stage company, they needed AldenMC’s help in communicating Actavalon’s small molecule’s capability to restore the tumor suppressor activity of the mutant p53 proteins – the Holy Grail of all cancer cures.